Effectiveness, tolerability and safety of Direct Acting Antivirals in Mexican individuals with Hepatitis C virus genotype-1 and previous pegylated interferon and ribavirin therapy

BACKGROUND: Direct Acting Antivirals (DAAs) represent a large improvement in the treatment of chronic hepatitis C, resulting in <90% sustained virological response (SVR). There are no reports on the real-world DAA response for Mexico and few reports exist for Latin America. The aim of the study w...

Descripción completa

Detalles Bibliográficos
Autores principales: Melendez-Mena, Daniel, Mendoza-Torres, Miguel Angel, Sedeño-Monge, Virginia, García y García, Víctor Hugo, Rivera-García, Elain, Sánchez-Reza, Laura, Baxin Domínguez, María del Carmen, Guzmán-Flores, Belinda, Martinez-Laguna, Ygnacio, Coronel Espinoza, José Manuel, Galindo-Santiago, Iván, Flores-Alonso, Juan Carlos, Vallejo-Ruiz, Verónica, Cortes-Hernandez, Paulina, Reyes-Leyva, Julio, Sosa-Jurado, Francisca, Santos-López, Gerardo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: PeerJ Inc. 2021
Materias:
Virology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8451435/
https://www.ncbi.nlm.nih.gov/pubmed/34616602
http://dx.doi.org/10.7717/peerj.12051

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8451435/
https://www.ncbi.nlm.nih.gov/pubmed/34616602
http://dx.doi.org/10.7717/peerj.12051

Ejemplares similares